Dynavax Technologies (DVAX) Stock Price, News & Analysis

Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Key Stats

• Today's Range: $10.04 to $10.30
• 50-Day Range: $9.77 to $11.36
• 52-Week Range: $9.22 to $14.63
• Volume: 1.16 million shs
• Average Volume: 1.87 million shs
• Market Capitalization: $1.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $24.33
• Consensus Rating: Moderate Buy

Dynavax Technologies Stock Analysis - MarketRank™

Dynavax Technologies scored higher than 93% of companies evaluated by MarketBeat, and ranked 76th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dynavax Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Dynavax Technologies has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 53.13%

Earnings Growth

Earnings for Dynavax Technologies are expected to grow by 53.13% in the coming year, from $0.32 to $0.49 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dynavax Technologies is -22.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dynavax Technologies is -22.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dynavax Technologies has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.97% of the float of Dynavax Technologies has been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Dynavax Technologies has recently decreased by 4.42%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dynavax Technologies does not currently pay a dividend.

Dividend Growth

Dynavax Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -1.59

Percentage of Shares Shorted

12.97% of the float of Dynavax Technologies has been sold short.

Short Interest Ratio / Days to Cover

Dynavax Technologies has a short interest ratio ("days to cover") of 8.3.

Change versus previous month

Short interest in Dynavax Technologies has recently decreased by 4.42%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 1.31

News Sentiment

Dynavax Technologies has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.11 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Dynavax Technologies this week, compared to 6 articles on an average week.

Search Interest

1 people have searched for DVAX on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Dynavax Technologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $41,116.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.98% of the stock of Dynavax Technologies is held by insiders.

Percentage Held by Institutions

96.96% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DVAX Stock Analysis - Frequently Asked Questions

How have DVAX shares performed this year?

Dynavax Technologies' stock was trading at $12.77 at the beginning of 2025. Since then, DVAX shares have decreased by 20.8% and is now trading at $10.12.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Corporation (NASDAQ:DVAX) posted its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. The biopharmaceutical company earned $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive trailing twelve-month return on equity of 5.10%.
Read the conference call transcript.

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' top institutional investors include State Street Corp (5.45%), Chicago Capital LLC (4.35%), Geode Capital Management LLC (2.24%) and Blair William & Co. IL (1.90%). Insiders that own company stock include Andrew A F Hack, Robert Janssen, Francis Cano, Scott Dunseth Myers, David F Novack and Justin Burgess.
View institutional ownership trends.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dynavax Technologies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/01/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DVAX
• CIK: 1029142
• Web: www.dynavax.com
• Phone: (510) 848-5100
• Fax: 510-848-1327
• Employees: 350
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Dynavax Technologies: $24.33
• High Price Target: $32.00
• Low Price Target: $10.00
• Potential Upside/Downside: +140.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 31.63
• P/E Growth: N/A
• Net Income: $27.31 million
• Net Margins: -16.67%
• Pretax Margin: -15.56%
• Return on Equity: 5.10%
• Return on Assets: 3.00%

Debt

• Debt-to-Equity Ratio: 0.45
• Current Ratio: 6.65
• Quick Ratio: 6.01

Sales & Book Value

• Annual Sales: $277.25 million
• Price / Sales: 4.28
• Cash Flow: $0.16 per share
• Price / Cash Flow: 63.91
• Book Value: $4.54 per share
• Price / Book: 2.23

Miscellaneous

• Outstanding Shares: 117,270,000
• Free Float: 113,772,000
• Market Cap: $1.19 billion
• Optionable: Optionable
• Beta: 1.24